Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Personalized Model of Prognosis Stratification for Patients with Advanced HCC Receiving TACE Combined with PD-1/PD-L1 Inhibitors Plus Molecular Target Therapies

NCT06607120 is registered in ClinicalTrials.gov with Zhongda Hospital as lead sponsor.

NCT NCT06607120
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06607120 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Personalized Model of Prognosis Stratification for Patients with Advanced HCC Receiving TACE Combined with PD-1/PD-L1 Inhibitors Plus Molecular Target Therapies
Lead sponsor
Zhongda Hospital
Phase
Observational
Overall status
Recruiting
Start date
June 1, 2024
Completion date
March 1, 2025
Enrollment
950 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma